Back in March last year, the Indian government announced that it was granting its first compulsory license, for the anti-cancer drug marketed as Nexavar, whose $70,000 per year price-tag put it out of reach of practically everyone in India. Nexavar’s manufacturer, the German pharmaceutical (...)
Commentaires récents
A bientôt,
En tout cas il y a un air de famille, c’est sur !
philippe
Pas d’inquiétude à avoir, là bas ces boutiques se trouvent à tous les coins de rue (...)